Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Tourette's Syndrome
Interventions
DRUG

Ecopipam

Ecopipam is a selective antagonist of the dopamine D1 receptor family.

Trial Locations (11)

10065

Weill Cornell Medical School, New York

11030

North Shore-Long Island Jewish Hosptial, Manhasset

30322

Emory University School Of Medicine, Atlanta

33701

University of South Florida/Rothman Center for Neuropsychiatry, St. Petersburg

45228

Cincinnati Children's Hospital, Cincinnati

60637

University of Chicago Medical School, Chicago

63110

Washington University School of Medicine, St Louis

64108

Children's Mercy Kansas City, Kansas City

77030

Baylor College of Medicine, Houston

90024

UCLA, Los Angeles

07902

Overlook Hospital, Summit

Sponsors
All Listed Sponsors
collaborator

Psyadon Pharma

INDUSTRY

lead

Emalex Biosciences Inc.

INDUSTRY